Agreement creates runway for Profound’s incision–free and radiation–free therapies for the ablation of diseased tissue, to penetrate the largest healthcare market in the Middle East
Read more »
NeOnc Technologies (Nasdaq: NTHI) to Host Investor Conference Call to Present Data Updates from Ongoing NEO100-1 Phase 1/2a Clinical Trial and Compassionate Use Program
CALABASAS, Calif., Nov. 07, 2025 (GLOBE NEWSWIRE) — NeOnc Technologies Holdings, Inc. (NTHI) (“NeOnc” or the “Company”), a clinical–stage biopharmaceutical company [...] Read more »
PharmaJet® Signs Distribution Agreement with EVA Pharma to Provide Needle-free Injection Systems to Support Routine Polio Immunization in Egypt
GOLDEN, Colo. and CAIRO, Oct. 31, 2025 (GLOBE NEWSWIRE) — Read more »
Inteleos Opens Africa Office to Advance Basic Obstetric Point of Care Ultrasound (OPOCUS) Certification Across East Africa
ROCKVILLE, Md. and NAIROBI, Kenya, Oct. 30, 2025 (GLOBE NEWSWIRE) — Inteleos, a global nonprofit healthcare certification organization, expands its commitment to working on the ground in Africa to elevate the standard of global [...] Read more »
Curia Invests $4 Million to Enhance Sterile API Manufacturing
ALBANY, N.Y., Oct. 27, 2025 (GLOBE NEWSWIRE) — Curia Global, Inc. (Curia), a leading global research, development and manufacturing organization, today announced the completion of a $4 million investment to upgrade its two API [...] Read more »
Curia Investe US $4 Milhões para Aprimorar a Fabricação de APIs Estéreis
ALBANY, N.Y., Oct. 27, 2025 (GLOBE NEWSWIRE) — Curia Global, Inc. (Curia), uma organização líder global em pesquisa, desenvolvimento e fabricação, anunciou hoje a conclusão de um investimento [...] Read more »
Curia investiert 4 Mio. US-Dollar in die Optimierung der Herstellung steriler Wirkstoffe
ALBANY, New York, Oct. 27, 2025 (GLOBE NEWSWIRE) — Curia Global, Inc. (Curia), ein weltweit führendes Forschungs–, Entwicklungs– und Produktionsunternehmen, gab heute den Abschluss einer 4 Millionen US–Dollar [...] Read more »
Curia investit 4 millions de dollars pour renforcer la fabrication stérile de substances actives (API)
ALBANY, New York, 27 oct. 2025 (GLOBE NEWSWIRE) — Curia Global, Inc. (Curia), l’une des principales organisations de recherche, de développement et de fabrication sous contrat, a annoncé aujourd’hui [...] Read more »
L'usine de médicaments stériles Curia nommée fabricant de l'année dans le Massachusetts
ALBANY, N.Y., 22 oct. 2025 (GLOBE NEWSWIRE) — Curia Global, Inc. (Curia), une organisation leader dans la recherche, le développement et la fabrication sous contrat, a annoncé aujourd'hui que son usine de produits [...] Read more »
Curias Anlage für sterile Arzneimittel als Hersteller des Jahres in Massachusetts ausgezeichnet
ALBANY, N.Y., Oct. 22, 2025 (GLOBE NEWSWIRE) — Curia Global, Inc. (Curia), ein führendes Auftragsforschungs–, Entwicklungs– und Produktionsunternehmen, gab heute bekannt, dass seine Anlage für sterile [...] Read more »
Instalação de Medicamentos Estéreis da Curia Nomeada Fabricante do Ano de Massachusetts
ALBANY, N.Y., Oct. 22, 2025 (GLOBE NEWSWIRE) — A Curia Global, Inc. (Curia), uma organização líder em contratos de pesquisa, desenvolvimento e fabricação, anunciou hoje que sua [...] Read more »
Curia Sterile Drug Product Facility Named Massachusetts Manufacturer of the Year
ALBANY, N.Y., Oct. 21, 2025 (GLOBE NEWSWIRE) — Curia Global, Inc. (Curia), a leading contract research, development and manufacturing organization, today announced its Burlington, MA sterile drug product facility has [...] Read more »
Minovia Therapeutics Receives FDA Orphan Drug Designation for MNV-201 in Myelodysplastic Syndrome
HAIFA, Israel, Oct. 15, 2025 (GLOBE NEWSWIRE) — Minovia Therapeutics Ltd. (“Minovia” or the “Company”), a clinical–stage biotechnology company developing novel therapies to treat [...] Read more »
Nilo Therapeutics startet mit einer Serie-A-Finanzierung in Höhe von 101 Mio. USD zur Entwicklung einer neuen Medikamentenklasse, die auf neuronale Schaltkreise bei Immunerkrankungen abzielt, und ernennt Kim Seth zum Chief Executive Officer
NEW YORK, Oct. 09, 2025 (GLOBE NEWSWIRE) — Nilo Therapeutics, ein Biotechnologieunternehmen, das neuronale Schaltkreise nutzt, um die Immunhomöostase bei Krankheiten wiederherzustellen, startete heute mit einer [...] Read more »
Lancement de Nilo Therapeutics avec un financement de série A de 101 millions de dollars en vue de développer une nouvelle classe de médicaments ciblant les circuits neuronaux dans les maladies immunitaires, et nomination de Kim Seth au poste de directeur général
NEW YORK, 09 oct. 2025 (GLOBE NEWSWIRE) — Nilo Therapeutics, une société de biotechnologie qui mise sur les circuits neuronaux pour rétablir l’homéostasie immunitaire chez les patients malades, [...] Read more »